Coeptis Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	11	27	30	94	98	-
Market Cap Growth	-	-11.10%	-67.92%	-4.72%	-	-
Enterprise Value	8	23	28	96	100	0
PE Ratio	-1.26	-1.26	-0.80	-6.97	-10.75	-
PS Ratio	-	-	-	1250.00	3198.76	-
PB Ratio	2.62	6.20	6.75	39.88	-19.13	-
P/FCF Ratio	-3.69	-3.69	-7.76	-20.88	-31.38	-
P/OCF Ratio	-3.69	-3.69	-7.76	-20.88	-31.38	-
EV/Sales Ratio	-	-	-	1275.36	3260.04	-
EV/EBITDA Ratio	-1.14	-1.14	-0.78	-7.46	-11.55	-68.10
EV/EBIT Ratio	-1.09	-1.09	-0.76	-7.21	-11.13	-68.10
EV/FCF Ratio	-3.18	-3.18	-7.31	-21.31	-31.98	-85.28
Debt / Equity Ratio	0.28	0.28	0.46	1.74	-0.41	9.73
Debt / EBITDA Ratio	-0.06	-0.06	-0.06	-0.32	-0.24	-68.33
Debt / FCF Ratio	-0.17	-0.17	-0.53	-0.91	-0.67	-85.56
Quick Ratio	1.66	1.66	1.75	0.79	0.04	0.00
Current Ratio	1.76	1.76	1.81	0.79	0.04	0.00
Asset Turnover	0	0	0	0.00	0.13	0
Interest Coverage	-196.49	-196.49	-171.03	-70.87	-60.79	-
Return on Equity (ROE)	-738.80%	-738.80%	-1104.50%	-791.70%	357.10%	-13.30%
Return on Assets (ROA)	-300.20%	-300.20%	-511.90%	-22.80%	-3879.50%	-1.80%
Return on Capital (ROIC)	-388.05%	-388.05%	-525.31%	-218.36%	219.71%	-1.33%
Earnings Yield	-188.37%	-79.54%	-124.93%	-14.35%	-9.31%	-
FCF Yield	-64.12%	-27.08%	-12.89%	-4.79%	-3.19%	-
Buyback Yield / Dilution	-79.70%	-79.70%	-30.98%	39.66%	-944.93%	-
Total Shareholder Return	-79.70%	-79.70%	-30.98%	39.66%	-944.93%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).